UCART19

BIOLOGICAL2 trials

Sponsors

Institut de Recherches Internationales Servier

Conditions

B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia

Phase 1

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

CompletedNCT02746952

Institut de Recherches Internationales ServierB-cell Acute Lymphoblastic Leukemia

Start: 2016-08-01End: 2020-07-28Updated: 2021-10-01

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

CompletedNCT02808442

Institut de Recherches Internationales ServierRefractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

Start: 2016-06-03End: 2020-11-04Updated: 2021-10-08

Related Papers

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.

2022-10-1091 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.

2020-12-01273 citations

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2018-11-2986 citations